A. M. Schmidt. (2018). “Highlighting Diabetes Mellitus: The Epidemic Continues.” Arterioscler Thromb Vasc Biol., vol. 38, no. 1, pp. e1-e8, 2018.
 A. American Diabetes. (2015). “(2) Classification and diagnosis of diabetes.” Diabetes Care, vol. 38, Suppl, pp. S8-S16, 2015.
 P. Zimmet, K. G. Alberti, D. J. Magliano, and P. H. Bennett. (2016). “Diabetes mellitus statistics on prevalence and mortality: facts and fallacies.” Nat Rev Endocrinol, vol. 12, no. 10, pp. 616-622, 2016.
 K. T. Kao and M. A. Sabin. (2016). “Type 2 diabetes mellitus in children and adolescents.” Aust Fam Physician, vol. 45, no. 6, pp. 401-406, 2016.
 Y. Zheng, S. H. Ley, and F. B. Hu. (2018). “Global aetiology and epidemiology of type 2 diabetes mellitus and its complications.” Nat Rev Endocrinol, vol. 14, no. 2, pp. 88-98, 2018.
 M. Hanefeld, H. Fleischmann, T. Siegmund, and J. Seufert. (2020). “Rationale for Timely Insulin Therapy in Type 2 Diabetes Within the Framework of Individualised Treatment: 2020 Update.” Diabetes Ther, vol. 11, no. 8, pp. 1645-1666, 2020.
 D. R. Owens. (2013). “Clinical evidence for the earlier initiation of insulin therapy in type 2 diabetes.” Diabetes Technol Ther, vol. 15, no. 9, pp. 776-785, 2013.
 S. E. Inzucchi, R. M. Bergenstal, J. B. Buse, M. Diamant, E. Ferrannini, M. Nauck, A. L. Peters, A. Tsapas, R. Wender, and D. R. Matthews. (2012). “Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).” Diabetologia, vol. 55, no. 6, pp. 1577-1596, 2012.
 C. L. Morgan, C. D. Poole, M. Evans, A. H. Barnett, S. Jenkins-Jones, and C. J. Currie. (2012). “What next after metformin? A retrospective evaluation of the outcome of second-line, glucose-lowering therapies in people with type 2 diabetes.” J Clin En-docrinol Metab, vol. 97, no. 12, pp. 4605-4612, 2012.
 M. Ridderstrale, K. R. Andersen, C. Zeller, G. Kim, H. J. Woerle, U. C. Broedl, and E.-R. H. H. S. T. Investigators. (2014). “Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.” Lancet Diabetes Endocrinol, vol. 2, no. 9, pp. 691-700, 2014.
 M. Nauck. (2016). “Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.” Diabetes Obes Metab, vol. 18, no. 3, pp. 203-216, 2016.
 S. P. Marso, G. H. Daniels, K. Brown-Frandsen, P. Kristensen, J. F. Mann, M. A. Nauck, S. E. Nissen, S. Pocock, N. R. Poulter, L. S. Ravn, W. M. Steinberg, M. Stockner, B. Zinman, R. M. Bergenstal, J. B. Buse, L. S. Committee, and L. T. Investigators. (2016). “Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.” N Engl J Med., vol. 375, no. 4, pp. 311-322, 2016.
 N. Rachdaoui. (2020). “Insulin: The Friend and the Foe in the Development of Type 2 Diabetes Mellitus.” Int J Mol Sci., vol. 21, no. 5, 2020.
 F. A. M. Al-Omary. (2017). “Gliclazide.” Profiles Drug Subst Excip Relat Methodol, vol. 42, pp. 125-192, 2017.
 W. A. Nuffer and J. M. Trujillo. (2015). “Liraglutide: A New Option for the Treatment of Obesity.” Pharmacotherapy, vol. 35, no. 10, pp. 926-934, 2015.
 P. M. O'Neil, A. L. Birkenfeld, B. McGowan, O. Mosenzon, S. D. Pedersen, S. Wharton, C. G. Carson, C. H. Jepsen, M. Kabisch, and J. P. H. Wilding. (2018). “Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial.” Lancet, vol. 392, no. 10148, pp. 637-649, 2018.
 C. Tzanetakos, A. Melidonis, C. Verras, G. Kourlaba, and N. Maniadakis. “Cost-Effectiveness Analysis of Liraglutide Versus Sitagliptin or Exenatide in Patients With Inadequately Controlled Type 2 Diabetes On Oral Antidiabetic Drugs In Greece.” Value Health, vol. 17, no. 7, p. A345, 2014.
 N. Peradze, O. M. Farr, N. Perakakis, I. Lazaro, A. Sala-Vila, and C. S. Mantzoros. (2019). “Short-term treatment with high dose liraglutide improves lipid and lipoprotein profile and changes hormonal mediators of lipid metabolism in obese patients with no overt type 2 diabetes mellitus: a randomized, placebo-controlled, cross-over, double-blind clinical trial.” Cardiovasc Diabetol, vol. 18, no. 1, p. 141, 2019.
 Y. R. Wu, X. Y. Shi, C. Y. Ma, Y. Zhang, R. X. Xu, and J. J. Li. (2019). “Liraglutide improves lipid metabolism by enhancing cholesterol efflux associated with ABCA1 and ERK1/2 pathway.” Cardiovasc Diabetol, vol. 18, no. 1, p. 146, 2019.
 M. Fan, H. Jiang, Y. Zhang, Y. Ma, L. Li, and J. Wu. (2018). “Liraglutide Enhances Autophagy and Promotes Pancreatic beta Cell Proliferation to Ameliorate Type 2 Diabetes in High-Fat-Fed and Streptozotocin-Treated Mice.” Med Sci Monit, vol. 24, pp. 2310-2316, 2018.
 M. Li, Y. Yang, D. Jiang, M. Ying, Y. Wang, and R. Zhao. (2017). “Efficacy and safety of liraglutide versus sitagliptin both in combination with metformin in patients with type 2 diabetes: A systematic review and meta-analysis.” Medicine (Baltimore), vol. 96, no. 39, p. e8161, 2017.